{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:10:08Z","timestamp":1792800608382,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T00:00:00Z","timestamp":1741132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"National Youth Science Fund Project","award":["82200252"],"award-info":[{"award-number":["82200252"]}]},{"name":"Research Fund of Anhui Institute of translational medicine","award":["2023zhyx-C81"],"award-info":[{"award-number":["2023zhyx-C81"]}]},{"name":"Anhui Medical University School Research Fund Project","award":["2023xkj160"],"award-info":[{"award-number":["2023xkj160"]}],"id":[{"id":"https:\/\/ror.org\/03xb04968","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370225"],"award-info":[{"award-number":["82370225"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"DOI":"10.1186\/s12916-025-03968-5","type":"journal-article","created":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T19:48:16Z","timestamp":1741117696000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Elevated CD10\u2212 neutrophils correlate with non-response and poor prognosis of CD19 CAR T-cell therapy for B-cell acute lymphoblastic leukemia"],"prefix":"10.1186","volume":"23","author":[{"given":"Jinli","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furun","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyang","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunyi","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,5]]},"reference":[{"issue":"18","key":"3968_CR1","doi-asserted-by":"publisher","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","volume":"118","author":"RJ Brentjens","year":"2011","unstructured":"Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817\u201328.","journal-title":"Blood"},{"issue":"224","key":"3968_CR2","doi-asserted-by":"publisher","first-page":"224ra225","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19\u201328z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra225.","journal-title":"Sci Transl Med"},{"issue":"1","key":"3968_CR3","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1038\/s41467-020-19774-x","volume":"11","author":"F An","year":"2020","unstructured":"An F, Wang H, Liu Z, Wu F, Zhang J, Tao Q, et al. Influence of patient characteristics on chimeric antigen receptor T cell therapy in B-cell acute lymphoblastic leukemia. Nat Commun. 2020;11(1):5928.","journal-title":"Nat Commun"},{"issue":"5","key":"3968_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378(5):449\u201359.","journal-title":"N Engl J Med"},{"issue":"10299","key":"3968_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","volume":"398","author":"BD Shah","year":"2021","unstructured":"Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491\u2013502.","journal-title":"Lancet"},{"issue":"15","key":"3968_CR6","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/JCO.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S, et al. Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-ALL. J Clin Oncol. 2021;39(15):1650\u20139.","journal-title":"J Clin Oncol"},{"key":"3968_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2021.107742","volume":"96","author":"Y Pan","year":"2021","unstructured":"Pan Y, Wang H, An F, Wu F, Tao Q, Li Y, et al. CD4(+)CD25(+)CD127(low) regulatory T cells associated with the effect of CD19 CAR-T therapy for relapsed\/refractory B-cell acute lymphoblastic leukemia. Int Immunopharmacol. 2021;96: 107742.","journal-title":"Int Immunopharmacol"},{"issue":"6537","key":"3968_CR8","doi-asserted-by":"publisher","first-page":"eaba1786","DOI":"10.1126\/science.aba1786","volume":"372","author":"EW Weber","year":"2021","unstructured":"Weber EW, Parker KR, Sotillo E, Lynn RC, Anbunathan H, Lattin J, et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science. 2021;372(6537):eaba1786.","journal-title":"Science."},{"issue":"6","key":"3968_CR9","first-page":"372","volume":"16","author":"NN Shah","year":"2019","unstructured":"Shah NN, Fry TJ. Mechanisms of resistance to CAR T cell therapy. Nat Rev Clin Oncol. 2019;16(6):372\u201385.","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"3968_CR10","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1182\/blood.2020009515","volume":"138","author":"K Wudhikarn","year":"2021","unstructured":"Wudhikarn K, Flynn JR, Riviere I, Gonen M, Wang X, Senechal B, et al. Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy. Blood. 2021;138(7):531\u201343.","journal-title":"Blood"},{"issue":"12","key":"3968_CR11","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","volume":"22","author":"M Ruella","year":"2023","unstructured":"Ruella M, Korell F, Porazzi P, Maus MV. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat Rev Drug Discov. 2023;22(12):976\u201395.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"3968_CR12","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","volume":"41","author":"KE de Visser","year":"2023","unstructured":"de Visser KE, Joyce JA. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth. Cancer Cell. 2023;41(3):374\u2013403.","journal-title":"Cancer Cell"},{"issue":"3","key":"3968_CR13","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ccell.2023.02.001","volume":"41","author":"JM Adrover","year":"2023","unstructured":"Adrover JM, McDowell SAC, He XY, Quail DF, Egeblad M. NETworking with cancer: the bidirectional interplay between cancer and neutrophil extracellular traps. Cancer Cell. 2023;41(3):505\u201326.","journal-title":"Cancer Cell"},{"issue":"3","key":"3968_CR14","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/s41577-021-00571-6","volume":"22","author":"CC Hedrick","year":"2022","unstructured":"Hedrick CC, Malanchi I. Neutrophils in cancer: heterogeneous and multifaceted. Nat Rev Immunol. 2022;22(3):173\u201387.","journal-title":"Nat Rev Immunol"},{"issue":"20","key":"3968_CR15","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1182\/blood-2018-11-844548","volume":"133","author":"MA Giese","year":"2019","unstructured":"Giese MA, Hind LE, Huttenlocher A. Neutrophil plasticity in the tumor microenvironment. Blood. 2019;133(20):2159\u201367.","journal-title":"Blood"},{"issue":"6","key":"3968_CR16","doi-asserted-by":"publisher","first-page":"e20220011","DOI":"10.1084\/jem.20220011","volume":"219","author":"DF Quail","year":"2022","unstructured":"Quail DF, Amulic B, Aziz M, Barnes BJ, Eruslanov E, Fridlender ZG, et al. Neutrophil phenotypes and functions in cancer: a consensus statement. J Exp Med. 2022;219(6):e20220011.","journal-title":"J Exp Med."},{"issue":"5","key":"3968_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.616","volume":"10","author":"Y Wang","year":"2022","unstructured":"Wang Y, Wang J, Zhu F, Wang H, Yi L, Huang K, et al. Elevated circulating myeloid-derived suppressor cells associated with poor prognosis in B-cell non-Hodgkin\u2019s lymphoma patients. Immun Inflamm Dis. 2022;10(5): e616.","journal-title":"Immun Inflamm Dis"},{"issue":"4","key":"3968_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1111\/imcb.12728","volume":"102","author":"J Zhou","year":"2024","unstructured":"Zhou J, Xiao H, Wang Z, Wang H, Liang X, Zhai Z, et al. CD14(-)CD10(-)CD45(+)HLA-DR(-)SSC(+) neutrophils may be granulocytic myeloid-derived suppressor cell-like cells and relate to disease progression in non-Hodgkin\u2019s lymphoma patients. Immunol Cell Biol. 2024;102(4):256\u201368.","journal-title":"Immunol Cell Biol"},{"issue":"3","key":"3968_CR19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00262-021-03009-z","volume":"71","author":"X Zhang","year":"2022","unstructured":"Zhang X, Yang J, Li J, Li W, Song D, Lu XA, et al. Factors associated with treatment response to CD19 CAR-T therapy among a large cohort of B cell acute lymphoblastic leukemia. Cancer Immunol Immunother. 2022;71(3):689\u2013703.","journal-title":"Cancer Immunol Immunother"},{"issue":"15","key":"3968_CR20","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","volume":"133","author":"KA Hay","year":"2019","unstructured":"Hay KA, Gauthier J, Hirayama AV, Voutsinas JM, Wu Q, Li D, et al. Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood. 2019;133(15):1652\u201363.","journal-title":"Blood"},{"issue":"1","key":"3968_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/ejh.14132","volume":"112","author":"S Gupta","year":"2024","unstructured":"Gupta S, Kohorst M, Alkhateeb HB. Determinants of outcomes and advances in CD19-directed chimeric antigen receptor therapy for B-cell acute lymphoblastic leukemia. Eur J Haematol. 2024;112(1):51\u201363.","journal-title":"Eur J Haematol"},{"issue":"6","key":"3968_CR22","doi-asserted-by":"publisher","first-page":"5688","DOI":"10.3390\/ijms24065688","volume":"24","author":"V Wittibschlager","year":"2023","unstructured":"Wittibschlager V, Bacher U, Seipel K, Porret N, Wiedemann G, Haslebacher C, et al. CAR T-Cell persistence correlates with improved outcome in patients with B-cell lymphoma. Int J Mol Sci. 2023;24(6):5688.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"3968_CR23","first-page":"2307","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141(19):2307\u201315.","journal-title":"Blood"},{"issue":"10","key":"3968_CR24","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1182\/blood-2016-04-713206","volume":"129","author":"O Marini","year":"2017","unstructured":"Marini O, Costa S, Bevilacqua D, Calzetti F, Tamassia N, Spina C, et al. Mature CD10(+) and immature CD10(-) neutrophils present in G-CSF-treated donors display opposite effects on T cells. Blood. 2017;129(10):1343\u201356.","journal-title":"Blood"},{"issue":"7","key":"3968_CR25","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/j.ymthe.2023.04.008","volume":"31","author":"B Zhang","year":"2023","unstructured":"Zhang B, Hu M, Ma Q, Li K, Li X, He X, et al. Optimized CAR-T therapy based on spatiotemporal changes and chemotactic mechanisms of MDSCs induced by hypofractionated radiotherapy. Mol Ther. 2023;31(7):2105\u201319.","journal-title":"Mol Ther"},{"issue":"11","key":"3968_CR26","doi-asserted-by":"publisher","first-page":"e003237","DOI":"10.1136\/jitc-2021-003237","volume":"9","author":"SA Nalawade","year":"2021","unstructured":"Nalawade SA, Shafer P, Bajgain P, McKenna MK, Ali A, Kelly L, et al. Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer. J Immunother Cancer. 2021;9(11):e003237.","journal-title":"J Immunother Cancer"},{"issue":"15","key":"3968_CR27","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1158\/0008-5472.CAN-21-1237","volume":"81","author":"DI Gabrilovich","year":"2021","unstructured":"Gabrilovich DI. The dawn of myeloid-derived suppressor cells: identification of arginase i as the mechanism of immune suppression. Cancer Res. 2021;81(15):3953\u20135.","journal-title":"Cancer Res"},{"key":"3968_CR28","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fimmu.2017.00093","volume":"8","author":"PC Rodriguez","year":"2017","unstructured":"Rodriguez PC, Ochoa AC, Al-Khami AA. Arginine metabolism in myeloid cells shapes innate and adaptive immunity. Front Immunol. 2017;8:93.","journal-title":"Front Immunol"},{"key":"3968_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.617699","volume":"11","author":"V Vonwirth","year":"2020","unstructured":"Vonwirth V, Bulbul Y, Werner A, Echchannaoui H, Windschmitt J, Habermeier A, et al. Inhibition of arginase 1 liberates potent T cell immunostimulatory activity of human neutrophil granulocytes. Front Immunol. 2020;11: 617699.","journal-title":"Front Immunol"},{"issue":"2","key":"3968_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/CJI.0b013e318194a6e8","volume":"32","author":"D Hollyman","year":"2009","unstructured":"Hollyman D, Stefanski J, Przybylowski M, Bartido S, Borquez-Ojeda O, Taylor C, et al. Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy. J Immunother. 2009;32(2):169\u201380.","journal-title":"J Immunother"},{"key":"3968_CR31","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920910347","volume":"12","author":"X Liu","year":"2020","unstructured":"Liu X, Wen J, Yi H, Hou X, Yin Y, Ye G, et al. Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release. Ther Adv Med Oncol. 2020;12: 1758835920910347.","journal-title":"Ther Adv Med Oncol"},{"issue":"1","key":"3968_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3\u20138.","journal-title":"Cancer Immunol Res"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03968-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-025-03968-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-025-03968-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,5]],"date-time":"2025-03-05T07:30:09Z","timestamp":1741159809000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-025-03968-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,5]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3968"],"URL":"https:\/\/doi.org\/10.1186\/s12916-025-03968-5","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,5]]},"assertion":[{"value":"4 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review boards at SHAMU (the Medical Ethics Committee and the Academic Committee at SHAMU) (No. SL-YX: 2015\u201306-01). All participants provided written informed consent in accordance with the principles of the Declaration of Helsinki prior to enrollment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"138"}}